Nuphase Therapeutics (Shanghai) Co. Ltd. has disclosed compounds acting as interleukin-17A/A homodimer and IL-17A/F heterodimer inhibitors reported to be useful for the treatment of cancer, autoimmune and inflammatory diseases.